title: In vitro and in vivo antitumoral activity of free, and encapsulated taxol.
abstract: The anti-tumoral activity of taxol encapsulated either in liposomes or in nanocapsules was compared with that of free taxol, using the P388 and L1210 leukaemia test systems. The in vitro inhibition of cell growth was measured after 48 h and 96 h exposure to various concentrations of taxol. With P388 cells, the inhibitory activities of the three forms of the drug were similar. With the L1210 cells, however, the concentrations required for a 50 per cent inhibition of cell growth (IC50) after 48 h exposure to the drug were greater for nanocapsules than for liposomes or free taxol, the values being 0.060, 0.043 and 0.035 micrograms ml-1, respectively. However, a greater efficiency of nanocapsules was observed after 96 h exposure. Using cytomorphometric analysis, no difference was found between L1210 cells treated either with free or encapsulated taxol. In vivo, mice bearing P388 leukaemia, and treated either with taxol solubilized with 5 per cent DMSO + 5 per cent cremophor in saline solution, or with taxol encapsulated in liposomes (IP daily dose of 12.5 mg Kg-1 body weight x 4 days) showed ILS values of 65.8% and 67.9% respectively. Nanocapsules proved to be toxic, apparently due to their composition: this problem is currently under investigation.
authors.affiliation: UFR de Pharmacie, Domaine de la Merci, La Tronche, France.
authors.forename: M H
authors.initials: MH
authors.lastname: Bartoli
authors.forename: M
authors.initials: M
authors.lastname: Boitard
authors.forename: H
authors.initials: H
authors.lastname: Fessi
authors.forename: H
authors.initials: H
authors.lastname: Beriel
authors.forename: J P
authors.initials: JP
authors.lastname: Devissaguet
authors.forename: F
authors.initials: F
authors.lastname: Picot
authors.forename: F
authors.initials: F
authors.lastname: Puisieux
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000627:therapeutic use; D002214:Capsules; D004339:Drug Compounding; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000401:mortality; D007941:Leukemia P388 / Q000188:drug therapy* / Q000401:mortality; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008081:Liposomes; D051379:Mice; D017239:Paclitaxel; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D002214:Capsules; D008081:Liposomes; D017239:Paclitaxel